Bleomycin induces fibrotic transformation of bone marrow stromal cells to treat height loss of intervertebral disc through the TGFβR1/Smad2/3 pathway

Xiao Yang  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Zhiqian Chen  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Chen Chen  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Chen Han  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Yifan Zhou  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Xunlin Li  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Haijun Tian  
shanghai 9th

Xiaofei Cheng  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Kai Zhang  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

An Qin  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Tangjun Zhou  
Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Jie Zhao (✉ profzhaojie@126.com)  
Shanghai Jiao Tong University School of Medicine  https://orcid.org/0000-0003-1000-5641

Research

Keywords: Intervertebral Disc Degeneration, Bleomycin, Bone Marrow Stromal Cells, Annulus Fibrosus Cells, Reparative Fibrosis, TGFβ-TGFβR1-SMAD2/3 Signaling Pathway
Abstract

**Background:** Lower back pain is often accredited to loss of intervertebral disc (IVD) height and compromised spine stability as a result of intervertebral disc degeneration (IVDD). We aim to locally use Bleomycin to induce the fibrotic transformation of bone marrow stromal cells (BMSCs) as a means to induce reparative fibrosis to slow down the height loss.

**Methods:** IVD from patients were gathered for histological examination. The expression of transforming growth factor beta 1 (TGF-β) signaling pathway was determined by qPCR and western blotting. Nucleus pulposus (NP) cells, annulus fibrosus (AF) cells and the Rats’ bone marrow stromal cells (BMSC) were cultured and their responsiveness to Bleomycin was evaluated by Cell Counting Kit-8, comet assay, transwell migration and wound healing assays. Rat IVDD models were created by puncture, rescued by Bleomycin injection and the effectiveness was evaluated by images (X-ray and MRI) and atomic force microscope.

**Results:** Histological examination showed increased levels of pro-fibrotic markers in IVDD tissues from patients. AF cells and BMSC cells was induced to adopt to a pro-fibrotic phenotype with increased expression fibrotic markers Col1a1, Col3a1, FSP1. The pro-fibrotic effect of Bleomycin on AF cells and BMSCs was in part due to the activation of the TGFβ-TGFβR1-SMAD2/3 signaling pathway. Pharmacological inhibition or gene knock-down of TGFβR1 could mitigate the pro-fibrotic effects.

**Conclusion:** Locally injection of Bleomycin in rats’ IVD induced rapid fibrosis and maintained its height through TGFβ-TGFβR1-SMAD2/3 signaling pathway.

Background

Low back pain and other spine disorders due to intervertebral disc degeneration affects over 600 million of people worldwide, imposing substantial burden to the medical and socioeconomic structures of all developed countries[1]. Intervertebral disc degeneration is a complicated process involving three main tissues: the nucleus pulposus (NP), a proteoglycan-rich gelatinous center of the intervertebral disc; the outer and inner annulus fibrosus (AF), a partially concentric collagen-rich fibrocartilaginous tissue surrounding the NP; and two cartilaginous endplates that interface with the vertebral bodies superiorly and inferiorly[2, 3]. Intervertebral disc degeneration is a progressive, cell-mediated cascade of molecular, structural and biomechanical changes: degeneration starts in the NP where the reduction in proteoglycan content and a decrease in the ratio of proteoglycan to collagen results in loss of hydrostatic properties leading to structural wear and compromised biomechanical functions[4]. Continued dehydration results in the collapse of the NP, loss of intervertebral disc height and the gradual loss of NP-AF borders ultimately progressing to complete degeneration of the entire intervertebral disc. This causes spine instability and nerve root compression evoking chronic back pain[4, 5].

During degeneration in discs, ruptured NP and AF would recruit multiple cells to finish the repair process, of which the most important cells are fibroblastic cells and MSCs[6], but due to the low cell population
and lack of nutrient supply to the intervertebral disc tissues, self-regeneration is limited[5, 7, 8]. Conventional treatment strategies are largely limited to symptomatic relief with limited long-term efficacy[9-11], and this spinal fusion surgery does no restore biomechanical properties but may in fact induce degeneration of adjacent vertebral bodies due to the increased mechanical stress they have to sustain[12]. Cell-based approach has also been studied in the past few years and one of the most focused methods is disc regeneration via MSCs transplantation[13-15]. Moreover, recent researches have unveiled that there are some MSCs distributed around the outer AF region and endplate[16]. So from a different perspective that a former approach of our studies by injection of autologous dermal fibroblast cells into degenerative intervertebral to treat IVDD[17]: We showed that the induction of reparative fibrosis combined with two essential cells in discs, one is to induce the fibrotic phenotype of MSCs, and the other is to promote the fibroblastic-like cell AF cells.

Bleomycin is a cytotoxic chemotherapeutic compound used in the treatment of lymphoma, leukemia, squamous cell carcinomas, and some genital tract tumors. Its major side-effect as an anti-cancer agent is the induction of fibrosis particularly pulmonary fibrosis. Interestingly, despite the mechanism of DNA damage to treat cancer, Lin X et al used it's pro-fibrotic function to induce the fibrosis of extracranial arteriovenous malformation by intralesional interstitial Bleomycin injection, just like a sclerosant[18]. Their prospective studies involved 34 patients and finally successfully cure 27 of them making an extraordinary result, and this local-injection therapy was once a mouth with a low dose less than 400 mg or 5 mg/kg, which contributed to less side effects[19, 20]. Based on these studies, we hypothesized that the pro-fibrotic effects of Bleomycin injecting locally could on the one hand induce the fibrosis of MSCs and AF cells to maintain the disc height, on the other hand it could accelerate the absorption of herniated NP in degenerative intervertebral discs.

In this study, we investigated the potential use of Bleomycin to induce reparative fibrosis as a means to maintain intervertebral disc height, and we tried to use it to induce the fibrosis phenotype of BMSCs and offer an alternative treatment in degeneration caused height loss. We also explored the potential molecular mechanism underlying the effects Bleomycin particularly in terms of the TGFβ-SMAD2/3 signaling, one of the key pathways in the fibrotic process.

**Methods**

**Intervertebral discs specimens**

Intervertebral discs (≥ 5 mm) were obtained from 12 patients, including 7 males and 5 females with a combined average age of 52.8 ± 12.8 years (age range of 30-74 years) and diagnosed with lumbar disc herniation (LDH) or degenerative lumbar spondylolisthesis (DLS) (Figure 1A – C; Table 1). The NP were sampled from L4/5 and subjected to histological and immunohistochemical analyses. Intervertebral disc degeneration was evaluated using the Pfirrmann grading system.

**Isolation and cell culture of BMSCs**
6-week-old male Sprague-Dawley rats (Shanghai Lab, Animal Research Center Co. Ltd, Shanghai, China) were killed by cervical dislocation and soaked in the 75% ethanol for 10 min. Extraction and isolation of BMSCs from two lower legs of SD rats with sterile operation, BMSCs were cultured in Minimum Essential Medium α (MEMα) supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA, USA).

**Culture of NP and AF cell-lines**

The Rat's NP and AF cell are immortalized cell lines[21] which were kindly gifted by Dr. Chen Di at the Department of Orthopedic Surgery, Rush University Medical Center (Chicago, IL, USA). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA, USA).

**RNA extraction and real-time quantitative PCR (qPCR) analyses**

Total RNA were isolated from tissues and cells using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) as per manufacturer’s protocol. First strand complementary DNAs (cDNAs) were reversed transcribed from extracted RNAs using the cDNA Synthesis Kit (Takara Bio, Otsu, Japan). Relative mRNA expression was determined by RT-PCR using the GoTaq 1-step RT-qPCR System (Promega, Madison, WI, USA) followed by agarose gel electrophoresis (Bio-Rad Laboratories, Hercules, CA, U.S.A). Real-time qPCR was conducted using the TB Green Premix Ex Taq Kit (Takara Bio) on an Applied Biosystems QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher Scientific). Specific primer pairs were designed using NCBI BLAST and sequences provided in Table 2. The gene expression of GAPDH or β-actin was used as internal control. Target gene expression levels were determined using the \(2^{-\Delta\Delta CT}\) method. The mean CT value of target genes in the experimental groups were normalized to the CT value of GAPDH or β-actin to give a \(\Delta CT\) value. This was then further normalized to control samples to obtain \(\Delta\Delta CT\).

**Cell viability analysis**

Cell viability following Bleomycin treatment was evaluated using the Cell Counting Kit-8 (CCK-8; Dojindo Laboratories Co., Ltd, Kumamoto, Japan). Cells seeded onto 96-well plates at a density of 8×10^3 cells/well the day before were treated with increasing concentrations of Bleomycin sulfate (1, 5 and 10 \(\mu\)g/ml, dissolved in PBS; Selleck Chemicals, Houston, TX, USA) for 24, 48, 72, and 96 hours. NP, AF and BMSC cells were cultured in DMEM, DMEM/F12 or MEMα respectively, all supplemented with 10% FBS and 1% penicillin/streptomycin (complete DMEM or complete DMEM/F12). Cell media containing Bleomycin were changed every 2 days. At the end of the experimental periods, cells were incubated with fresh complete media containing 10 \(\mu\)l of CCK-8 reagent for 1 hour at 37°C. Complete media containing CCK-8 reagent but no cells and untreated cells were used as a blank and mock controls respectively. The absorbances (measured as optical density; OD) at 450 nm were measured on an Infinite M200 Pro multimode microplate reader (Tecan Life Sciences, Männedorf, Switzerland). ODs of the Bleomycin treated groups were normalized to corresponding blank ODs to account for background interference.
TGFβR1 siRNA knockdown

AF cells seeded onto 6-well plates at a density of 1×10⁵ cells/well the day before were transfected with small interfering RNA (siRNA) against TGFβR1 (siTGFβR1: Sense 5'-GGAGAUUGUUGGUACCCAAGG-3'; and Anti-sense 5'-UUGGGUACCAACAAUCUCAU-3') or with a scrambled siRNA control (NC: Sense 5'-UUCUCCGAACGUGACACGU-3'; and Anti-sense 5'-ACGUGACACGUUCAGAATT-3') (IBSBIO, Shanghai, China) using Lipofectamine 3000 transfection reagent in accordance with manufacturer's protocol. After 6 hours, media containing transfection reagent and siRNAs were removed and replaced with fresh complete media. Twenty-four hours post-transfection cells were harvested for total protein or total RNA extraction.

Comet analysis (single cell gel electrophoresis)

The method for comet analysis or single cell gel electrophoresis (SCGE) was performed as previously described[22, 23] Briefly, cultured AF cells, NP cells and BMSCs were trypsinized, centrifuged and resuspended in 1×PBS (Ca²⁺ and Mg²⁺ free; Gibco, Thermo Fisher Scientific) to final cell density of 1×10⁵ cells/ml. Next, 50 μl of cell suspensions were then mixed with 500 μl low melting point (LMP) agarose (1% at 37°C, Comet SCGE Assay Kit; Enzo Life Sciences, Farmingdale, NY, USA) and then 75 μl of cell-agarose mixture were spread onto glass slides precoated with 1% normal melting point (NMP) agarose and allowed to settle for 10 mins at 4°C in the dark. Slides were then immersed in pre-chilled Lysis Solution (Comet SCGE Assay Kit; Enzo Life Sciences) and incubated on ice for 1 hour. After lysis, the slides were placed on a horizontal gel electrophoresis unit containing electrophoretic Alkaline Solution (Comet SCGE Assay Kit; Enzo Life Sciences) for 60 mins at room temperature in the dark to allow the DNA to unwind. Electrophoresis was then carried out for 10 mins at 25 V and 300 mA (0.73 V/cm). After electrophoresis, slides were rinsed in distilled water, placed in neutralization solution (pH 7.5) to remove alkali and detergent, then dehydrated with 70% ethanol for 5 minutes and air-dried. Immediately before examination, the slides were stained with 100 μl of ethidium bromide (10 μg/ml) for 30 mins at room temperature in the dark. Comets were visualized under 400× magnification using epifluorescence microscopy (Leica DM4000 B; Leica Microsystems, Wetzlar, Germany)

Scratch-wound healing assay

The scratch-wound healing assay was performed to examine the effects of Bleomycin on collective migration and recolonization in a 2-dimensional environment. AF cells with or without TGFβR1 siRNA knockdown and BMSCs were cultured to 100% confluence. Under sterile conditions, a linear scratch line was made straight down the centre of the cell monolayer using the tip of a sterilized 200 μl micropipette tip. Cell media were carefully aspirated to remove cellular debris and floating cells and then replaced with fresh serum-free DMEM/F12 or MEMα without or with Bleomycin (5 or 10 μg/ml) ± TGFβR1 inhibitor (LY364947, 10μM; Selleck, USA). Phase contrast images were captured of the initial scratch wound for reference and designated time 0. Further images were captured at 24 and 48 hours, and the distance
between the leading cell edges at each time point was measured using ImageJ software (National Institutes of Health, USA).

**Millicell transwell migration assay**

The effects of Bleomycin on single cell migration through three-dimensional environment were examined using the transwell migration assay (Millicell Standing Cell Culture Inserts, 8 μm pore size; Merck-Millipore, Burlington, MA, USA). Briefly, AF cells with or without TGFβR1 siRNA knockdown and BMSCs were seeded into the upper chamber of the Millicell Standing Cell Culture inserts at a density of 8×10^4 cells/well in serum-free DMEM/F12 or MEM α media without or with Bleomycin (5 or 10 μg/ml) ± TGFβR1 inhibitor (LY364947, 10 μM; Selleck, USA ). The inserts were then placed into 24-well plates filled with complete media (FBS as chemoattractant source) and cultured for 24 hours. At the end of the experiment, media in the inserts were discarded and adherent cells were fixed in 4% paraformaldehyde (PFA) for 30 mins and then stained with 0.2% crystal violet for 5 mins. Cells adhering to the membrane inside the inserts (i.e. cells that have not migrated) were gently removed using a cotton-tipped applicator. Migrated cells on the other side of the inserts were imaged under a light microscope (Leica DM4000 B; Leica Microsystems) and staining intensity analyzed with Image Pro Plus 6.0 software to evaluate the ratio of integrated optical density (expressed as the IOD/area for each sample).

**Assessment of apoptosis and cell cycles by flow cytometry**

The effects of Bleomycin were evaluated using flow cytometry following staining with APC-Annexin V and propidium iodide (PI) for cell apoptosis or just PI for cell cycles based on apoptosis staining kit (Thermo Fisher Scientific) and PI/RNase Staining Buffer (BD pharmagen) according to manufacturer’s protocol. Cell suspensions were subjected to flow cytometry on a FACSCalibur Flow Cytometer (BD Biosciences) counting at least 10,000 events. The apoptotic rate was quantified based on the percentage of cells in the right upper (Q2; positive staining for APC-Annexin V and PI) and right lower (Q3; positive staining for APC-Annexin V and negative for PI) quadrant of the flow cytometric scatterplot.

**Senescence Assays**

NP cells and BMSCs were identified using the Senescence β-Galactosidase Staining Kit (Beyotime Biotechnology) according to manufacturer’s protocol. NP cells and BMSCs were seeded onto a 12-well plate at a density of 3×10^5 cells/well, following with 5 μg/ml bleomycin once or three times, every treat period lasts for three days. Then cells were fixed with Fixative Solution for 15 mins at RT and then incubated with β-Galactosidase Staining buffer at 37°C overnight in a dry incubator without CO₂. Then the cell percentage of positive cells were calculated.

**Western blot analysis**

Total cellular proteins were extracted from cultured cells using RIPA lysis buffer supplemented with phosphatase and protease inhibitors (Roche, Basel, Switzerland). Equal quantities of extracted proteins
(20-30 μg) were resolved on 10% or 12.5% SDS-PAGE gel and separated proteins electroblotted onto 0.22 μm PVDF membranes (Merck-Millipore). Membranes were blocked with 5% BSA-PBS at room temperature for 1 hour and then incubated with primary antibodies (diluted 1:1000 in 5% BSA-PBS) overnight (at least 16 hours) at 4°C. Primary antibodies against SMAD2 (Ser308, D43B4; rabbit mAb), phospho-SMAD2 (Ser465/467, 138D4; rabbit mAb), SMAD3 (C67H9; rabbit mAb), phospho-SMAD3 (Ser423/425, C25A9; rabbit mAb), SMAD2/3 (D7G7; rabbit mAb), phospho-SMAD2/3 (Ser465/467; Ser423/425; rabbit mAb), SMAD4 (D3M6U; rabbit mAb), PARP (#9542; rabbit mAb), Cleaved PARP (D64E10; rabbit mAb) and β-actin (D6A8; rabbit mAb) were purchased from Cell Signaling Technology (Danvers, MA, USA). Primary antibodies against FSP1(S100A4; rabbit mAb), TGFβ Receptor I (ab31013; rabbit mAb), type I collagen (ab6308; rabbit mAb), TGFβ1 (ab64715; rabbit mAb), P21 (ab109199; rabbit mAb) and P53 (ab26; mouse pAb) were obtained from Abcam (Cambridge, UK). Membranes were then washed extensively in Tris-buffered saline-Tween20 (TBST) and subsequently incubated with anti-rabbit IgG (H+L) (DyLight™ 800 4× PEG Conjugate; Cell Signaling Technology) secondary antibody (1:5000 dilution) for 1 hour at room temperature in the dark. Membranes were again extensively washed in TBST and protein immunoreactivity were detected on a LI-COR Odyssey Fluorescence Imaging System (LI-COR Biosciences, Lincoln, NE, USA). Semi-quantitative analysis of protein immunoreactive band intensity was measured using Image-Pro Plus 6.0 software and normalized to the internal loading control β-actin.

Animals and surgical procedures

All animal experimentation was approved by the Institutional Animal Care and Ethics Committee of Ninth People's Hospital, Shanghai Jiaotong University School of Medicine (Shanghai, China) and performed in accordance with the principles and procedures of the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and the Guidelines for Animal Treatment of Shanghai Jiaotong University. Six 8-week-old male Sprague-Dawley rats (Shanghai Lab, Animal Research Center Co. Ltd, Shanghai, China) were housed under pathogen-free conditions at 26-28°C and 50-65% humidity with 12-hour day/night cycle. Animals were fed standard rodent chow and had access to fresh water ad libitum. Before surgical procedures, rats were anesthetized by intraperitoneal injections of pentobarbital sodium (5 mg/100 g of body weight). The tails were sterilized with iodinated polyvinylpyrrolidone and then a ventral longitudinal skin incision was made over the tail to reveal the intervertebral disc at coccyx vertebrae 6-10. The intervertebral discs at Co6/7 were used as Sham controls and the intervertebral discs at Co7/8, Co8/9 and Co9/10 were used as experimental groups. Intervertebral discs were punctured with a 20-gauge sterile needle oriented perpendicular to the skin to make sure insertion at the center of the disc level through the AF into the NP. The incision was then sutured and rats were allowed post-operative recovery for two weeks. A group of mice (n = 3) were sacrificed and the tails extracted, cleaned of soft tissues and the vertebral column fixed in 4% PFA. To the remaining rats (n = 3), surgical exposure of the intervertebral discs at Co8/9 and Co9/10 was again carried out, and 5μl of Bleomycin at concentrations of 10 and 5 μg/ml was injected respectively into each disc. Incision was sutured and rats were allowed 2 and 4 weeks of post-treatment recovery. At the end of the experimental period, all remaining rats were sacrificed and the tails extracted, cleaned of soft tissues and the vertebral column fixed in 4% PFA.
**Histology and immunofluorescence staining**

Fixed intervertebral disc tissue samples were embedded into paraffin blocks then subjected to histological sectioning (5 μm thickness). For histological assessment, paraffin tissue sections were processed for Safranin O-Fast Green and Sirius Red staining in accordance with standard laboratory protocols. For immunofluorescence assessment, BMSCs were cultured in a slide with a confluence of 10% and fixed with 4%PFA, then these cell slides are with tissue sections to be de-paraffinized in graded xylene, rehydrated in graded alcohol solutions and then incubated in antigen retrieval buffer (Roche) at 37°C for 30 mins. After cooling to room temperature, slides were immersed in PBS (pH 7.4) and washed 3 times for 5 mins each. Auto-fluorescence quencher was added to the sections for 5 mins, and then blocked with blocking buffer for 30 mins at room temperature. Sections were subsequently incubated with primary antibodies in a wet box at 4°C overnight. Primary antibodies were used at 1:100 dilution and included anti-Col1α1, anti-Col2α1, anti-FSP1, anti-TGFβ, anti-TGFβR1, S100A9 (all purchased from Cell Signaling Technology) and anti-Keratin 18 (abs130128, absin). The next day, sections were washed with PBS and then incubated with Alexa Fluor 594 Conjugate secondary antibody (anti-rabbit, 1:500; Cell Signaling Technology) for 50 mins at room temperature in the dark. Sections were washed with PBS and then incubated with DAPI solution (Sigma-Aldrich, St Louis, MO, USA) for 10 mins in the dark to stain cell nuclei. Sections were subjected to final PBS washes, air-dried and then sealed with anti-fluorescence quenching tablets. Digital fluorescence images were captured under a Leica DM4000 B epifluorescence microscope (Leica Microsystems) and IOD measurements carried out using Image Pro Plus 6.0 software.

**Radiographic and magnetic resonance imaging (MRI) analysis**

Digital X-ray imaging of the punctured intervertebral discs were conducted in the anteroposterior axis with a 21 lp/mm detector that provides up to 5× geometric magnification (Faxitron VersaVision; Faxitron Bioptics LLC, Tucson, AZ. USA). MRI imaging of the same punctured intervertebral discs were carried out on a Siemens Magnetom Prisma E11 (Siemens Healthineers, Erlangen, Germany) with the following parameters: TR 3000 ms, TE 80 ms, 1.1 mm thickness, 0.22 mm interval, FOV 160×65 mm, and voxel size 0.25×0.25×1.1 mm.

**Atomic Force Microscopy (AFM)**

For AFM, the extracted punctured vertebrae were dissected to make paraffin section and nanoindentation was performed on a Park NX20 (Park Systems, South Korea) equipped with microspherical colloidal tips (R < 10 nm, nominal k ≈ 0.2 N/m, Tip:Si/Tipless/Top, cantilever Si/Al/Top; Park Systems). For a wide range of undulating surfaces, the scanning rate of 13 Hz was used. Large scanning rate can reduce drift, but it is generally only used for scanning small flat surfaces. Indentation was applied at a z-piezo displacement rate of 10 μm/s to a maximum load of ~120 nN using a Scan Asyst-Air probe, a curvature radius of 5 nm, and a force constant of 0.4 N/m. Young’s modulus, adhesion force, deformation parameters were evaluated.

**Statistical analysis**
Three independent experiments or repeated measurements were conducted for all data. Data are presented as the mean ± standard deviation (S.D.). Significance differences between study groups were obtained by Student's *t*-test or one-way analysis of variance (ANOVA) using SPSS 19.0 software (IBM Corporation, Armonk, NY, USA). Statistical significance was set at a *if the* *p*-value < 0.05 unless otherwise indicated.

**Results**

**Intervertebral disc degeneration correlates with fibrotic changes in NP in patients with lumbar disc herniation or degenerative lumbar spondylolisthesis.**

Degenerative and fibrotic changes in the intervertebral discs from 12 patients (patient details presented in Table 1) with lumbar disc herniation (LDH) or degenerative lumbar spondylolisthesis (DLS) were examined by MRI and Safranin O-Fast Green (SOFG) histological staining (Figure 1A-C). Pfirrmann grading based on MRI scans[5, 9] were then correlated with degree of fibrosis based on IOD of SOFG staining in the NP tissues of the intervertebral disc (Figure 1D). Consistent with the Pfirrmann grading for intervertebral disc degeneration, the higher the Pfirrmann grade, the greater the degree of the NP fibrosis in the intervertebral discs as demonstrated by increasing IOD score of Fast Green staining in the tissue sections (Figure 1D). That is, higher Pfirrmann grade is correlated with greater fibrotic changes in the NP tissues. We further noticed that with higher Pfirrmann grade such as IV and V (severe intervertebral disc degeneration with or without collapsed disc space), the fibrotic changes occur closer to the center of the NP tissues in the intervertebral disc (Figure 1B-D). No fibrosis was seen in intervertebral discs that were presented as Pfirrmann grade III (Figure 1A and D). We also examined the expression of fibrotic protein markers between the non-fibrotic and fibrotic regions of the NP tissues (Figure 1E and F). Compared with the non-fibrotic region, the fibrotic region expressed high levels of protein markers involved in fibrosis such as Col1a1, FSP1, TGFβ, and TGFβR1, and markedly decreased levels of Col2a1 (Figure 1E and F). Of these markers, FSP1 or fibroblast-specific protein-1 is highly expressed in fibroblasts and often used as fibrotic biomarker. The elevated expression of TGFβ and TGFβR1 suggests involvement of TGFβ signaling pathway in inducing fibrotic changes in the NP region during intervertebral disc degeneration.

**BMSCs was induced to acquire fibrotic phenotype by Bleomycin in vitro**

Our previous research using a cell-based approach have shown that induction of reparative fibrosis may offer beneficial effects against the progression of disc degeneration[17], and this process is associated with TGFβ signaling pathway. Considering the Bleomycin is an effective trigger to induce the upregulation of TGFβ in lung epithelium cells[24] and have been used in clinical situation before, we tried to use bleomycin combined with the multipotentiality of BMCSs to induce their fibrotic differentiation. In our research, Bleomycin could efficiently promote the migration of BMSCs in wound healing assay and transwell test (Figure 2A and 2B). Then, we showed that the cell viability of BMSCs were minimally deteriorated by the bleomycin in a concentration of 5 and 10ug/ml with a duration of 24 hours and 72 hours (Figure 2C), plus, as shown in the Suppl. Figure 1A and 1B, Although the apoptosis rate of BMSCs
increased (from 1.56 ± 0.1418%, n=3 to 3.19 ± 0.1601%, n=3), it is significantly lower than the NP cells (10.99 ± 0.9104%, n=3, Figure 3D and 3E). This enhancement in the ability of migration may be the consequence of changes happened in the molecular level, including the upregulation of TGFβR1 and TGFβ gene, as well as the expression of pro-fibrotic marker genes Col1a1, FSP1 and Fn1 (Figure 2F). Moreover, in the western blotting test we detected the slight elevation of TGFβR1, Col1a1, FSP1 with the stimulation of Bleomycin (Figure 2D). Immunofluorescence staining was carried out and we got the same result that TGFβ and Col1a1 increased with the Bleomycin (Figure 2E). To further confirmed our hypothesis, we use LY363947 (10 μM) [25], a TGFβR1 kinase activity inhibitor, to treat BMSC cells with Bleomycin and found that it markedly inhibited AF cell migration in both the scratch-wound healing and the transwell migration assay (Figure 2A and 2B), and it also could mitigate the upregulation of these pro-fibrotic marker genes and proteins mentioned above (Figure 2E and 2F).

**Bleomycin shows less cytotoxicity in AF cells and BMSCs in vitro**

Bleomycin is a chemotherapeutic cytotoxic compound that inhibits DNA metabolism and causes free-radical based DNA damage. So we assessed the effects of Bleomycin in the intervertebral disc. We first examined the cellular effects of Bleomycin on cells of the intervertebral discs particularly AF and NP cells. As shown in Figure 3A and B, Bleomycin exerted no cytotoxic effects on AF and NP cells following 24 hours treatment. For AF cells a trend of decrease in cell viability was observed at all doses of Bleomycin when cells were treated for 48 and 72 hours (the decreased viability rate of AF cells in a concentration of 5, 10 μg/ml for 48, 72, 96 hrs are 3% and 3%, -5% and 5%, 9% and 10%) , but the cytotoxic effect was only statistically significant in 96 hours (Figure 3A). On the other hand, significant reduction in cell viability was observed in NP cells treated with 10 μg/ml of Bleomycin for 48, 72, and 96 hours, and with 5 μg/ml of Bleomycin at 96 hours. (Figure 3B).

Next we employed flow cytometry to examine whether the cytotoxic effects of Bleomycin on NP cell viability was due to the induction of apoptosis. As shown in Figure 3C, a greater percentage of NP cells underwent cell death (necrotic and apoptotic) following 72 hours of Bleomycin treatment (at both 5 and 10 μg/ml) when compared with untreated controls as well as with AF cells. Both early and late apoptotic rate in NP cells were elevated significantly and dose-dependently (Figure 3D and 3E). On the other hand, the percentage of cells that underwent apoptosis (Figure 3D and 3E) in AF cells following Bleomycin treatment were similar to untreated controls. Consistent with elevated apoptotic tendencies, NP cells treated with Bleomycin was found to exhibit reduced expression of Cyclin D1, a cell cycle regulatory protein, and concomitant increase in the levels of cleaved Caspase 3, a crucial executor caspase in the apoptotic signaling cascade (Suppl. Figure 2B).

In single cell’s level, single cell gel electrophoresis or comet analysis was carried out. Figure 3F and 3G, Suppl. Figure 1C and 1D showed that Bleomycin dose-dependently induces significant DNA strand breaks and formation of markedly long comet tails in NP cells, evidenced by fluorescence intensity of DNA in the head and tail of the comet. Although DNA breaks and comet tails were also observed in Bleomycin treated AF cells and BMSCs (Figure 3F, Suppl. Figure 1C), the degree of DNA damage was significantly
less than in NP cells both in a dose- and time-dependent manner (Figure 3G and Suppl. Figure 1D). Taken together, our results show that NP cells are more susceptible to the cytotoxic and DNA damaging effects of Bleomycin than AF cells.

To further evaluate the side effect of Bleomycin, Senescence and cell cycles analyze were carried out on BMSCs and NP cells. For NP cells, bleomycin lead to the cell senescence whatever in the short-term treatment (once for three days) or the long-term treatment (three times and every stimulation lasts three days). On the contrary with the short-term treatment of the Bleomycin, the β-gal stained BMSCs had no change unless the time period increased to 9 days (Suppl. Figure 4A and 4B). From the perspective of lifespan, the Cell cycles of both cells were analyzed. As shown in the Suppl. Figure 4C and 4D, the cell distribution changed a lot in NP cells with an increased G1 phase and a decreased S phase, but for BMSCs the distribution of G1 phase, S phase and the G2 phase were quite the same with Bleomycin. Moreover, in PCR test there is an increase in gene expression like P21, CCND2 and CDK6, with a decreased CDK1, CDK2, CCNG2 and a CDK4 without change. For western blot assay there are no change in P53, P21 and cleaved PARP expression unless the decrease of full-length PARP (Suppl. Figure 5A and 5B).

**Bleomycin promotes AF cell migration in vitro via TGFβ-TGFβR1 signaling.**

Considering the AF cells are fibroblast-like cells and the TGFβ signaling pathway functioned in the fibroblast cells’ migration[26]. We detected the collective migratory behavior of AF cells using the in vitro scratch-wound healing assay. When compared to untreated controls, Bleomycin treatment dose-dependently enhanced AF cell migration and scratch-wound closure at 24 and 48 hours after the creation of the scratch wound creation (Figure 4A and Suppl. Figure 3A). To better mimic the in vivo behavior of individual AF cells, the transwell directional migration assay was performed. As shown in Figure 4C, AF cells that migrated through the transwell inserts were stained with crystal violet. Furthermore, consistent with the scratch-wound healing migration assay, Bleomycin treatment significantly increased the number of AF cells that migrated through the transwell insert (Suppl. Figure 3B). This suggests that activated TGFβ-TGFβR1 signaling is involved in mediating the effects of Bleomycin on AF cells. To further confirm that this was the case, TGFβR1 gene silencing in AF cells was carried out followed by Bleomycin treatment and migration assays. Consistent with the inhibitory effects of LY363947, the knockdown of TGFβR1 significantly attenuated Bleomycin-induced AF cell migration in both the scratch-wound healing and transwell migration assays (Figure 4B and 4D; and Suppl. Figure 3C and 3D).

**Bleomycin activates the TGFβ-TGFβR1-SMAD2/3 signaling pathway in AF cells**

To further decipher the molecular mechanism for the effects of Bleomycin on AF cells, biochemical analyses of gene and protein expression were carried out. As shown in Figure 5H and Suppl. Figure 6A, Bleomycin treatment induced the upregulation TGFβR1, TGFβR2 and TGFβ gene expression, as well as the expression of pro-fibrotic marker genes Col1a1, Col3a1 and Fn1, but no change in TGFβR3 gene expressions were observed. Pharmacological treatment with LY363947 inhibited Bleomycin-induced upregulation of TGFβR1, Col1a1, Col3a1 and Fn1 gene expression, but had little effect on TGFβ and
Silencing of TGFβR1, of which the knock-down efficiency is approximately 66.9%, significantly inhibited these changes better than LY363947 treatment but still couldn't inhibit TGFβ and TGFβR2 neither (Figure5H and Suppl. Figure 6B). None-the-less, these results indicate that Bleomycin induced AF cells to adopt a stronger fibrotic phenotype.

Immunoblot analyses were then carried out to examine the activation state of TGFβ-TGFβR1 signaling following Bleomycin treatment. In our immunoblot assays, we showed that Bleomycin treatment induced the expression of TGFβ and TGFβR1(Figure 5E), and the fibroblast marker FSP1 and profibrotic protein Col1a1 was similarly induced. On the other hand, silencing of TGFβR1 abolished the Bleomycin-induced protein expression of Col1a1 and FSP1 (Figure 5E). Furthermore, considering the downstream activation of SMAD2/3 transcription factors are important drivers of fibrosis, phosphorylation of SMAD2 and SMAD3 were analyzed following Bleomycin treatment (Figure 5A and 5B). However, pre-treatment of AF cells with LY363947 abolished the Bleomycin-induced activation of TGFβ-TGFβR1-SMAD2/3 signaling (Figure 5C and 5D). Similar inhibitory effects against Bleomycin-induced activation of TGFβ-TGFβR1-SMAD2/3 signaling was seen following TGFβR1 gene silencing (Figure 5F and 5G).

**Bleomycin induces fibrosis in degenerative intervertebral discs and maintains disc height in vivo.**

Using a needle puncture model of intervertebral disc degeneration in rats, we validated the potential use of Bleomycin to induce reparative fibrosis for the maintenance of disc height. Disc degeneration was allowed to develop for 2 weeks after needle puncture prior to administration of Bleomycin therapy for further 2 and 4 weeks (Suppl. Figure 6C, E and F). X-ray and MRI imaging were carried out to evaluate the effects of Bleomycin therapy (Figure 6A and 6B). X-ray radiographs show that the intervertebral discs that underwent needle puncture without subsequent Bleomycin treatment (Co7/8) showed progressive disc degeneration including height loss and disc collapse by the end of the experimental procedure (Figure 6A). MRI scans further show disc degeneration with progressive increase in grey levels (loss of T2 signal intensity) in the needle puncture only intervertebral discs (Figure 6B). In contrast, intervertebral discs that received Bleomycin therapy (Co8/9, 10 μg/ml; and Co9/10, 5 μg/ml) exhibit little degenerative features and maintenance of disc height despite the progressive loss of T2 signal intensity (Figure 6A and 6B). No degeneration of the intervertebral discs was observed in the sham group.

Histological examinations were then carried out to further assess the microstructural changes following Bleomycin therapy (Figure 6C and 6D). In both SOFG and Sirius Red stained intervertebral disc sections, AF and NP boundaries are clearly demarcated with no signs of disc degeneration (Figure 5C). Lack of collagen content was observed in the NP, whereas AF exhibits abundant type 3 and type 1 collagen (Figure 6C and 6D). Following needle puncture, we can see the loss of disc height and collapse of the intervertebral discs, increased type 3 collagen content in the NP indicating the onset of fibrosis (Figure 6C and 6D). However, no fibrosis into the remaining NP was observed (Figure 6C). In stark contrast, the boundaries between the AF and NP were not discernible in the Bleomycin therapy groups, with the NP completely filled with concentric lamellar type I collagen 1 (Figure 6C and 6D). Interestingly, to further investigated the cell distribution in the discs, we used KRT18 to stain the NP cells and S100A9 to stain the
AF cells and got the result that the ratio of the NP cells and AF cells reduced with Bleomycin stimulation (Suppl. Figure 7). The formation of the fibrous tissue and the increased fibroblast-like AF cells resulted in the maintenance of the intervertebral disc height (Figure 6C). Immunofluorescence staining was further carried out to assess the expression of pro-fibrotic markers in the intervertebral discs. As shown in Figure 6E, untreated degenerative discs exhibited slightly elevated expression of TGFβ, TGFβR1, Col1a1, FSP and decreased Col2a1 in the NP when compared to sham controls. Consistent with in vitro effects, Bleomycin administration significantly upregulated the expression of TGFβ, TGFβR1, Col1a1 and FSP in the AF and NP, but for Col2a1 (Suppl. Figure 5C) it showed a bi-directional effect, which increased in NP region and the deceased in AF region.

Atomic force microscopy (AFM) was subsequently carried out to evaluate the structural properties and stress tolerance, which was described by the Young's modulus (a measure of ability to withstand elastic/recoverable deformation under lengthwise tension or compression; a measure of stiffness), adhesion force, deformation and the topography correlated with the displacement curve (Suppl. Figure 8B and 8D). With puncture the Young's modulus increased in AF region, but after Bleomycin injection, the Young's modulus was even significantly higher (Figure 5F and 6G). Conversely, we observed elevation of the Young modulus in the NP region while puncture, but there was relative recovery after Bleomycin rescue (Suppl. Figure 8A and 8C), meaning the NP region could maintain the nature biomechanical status with bleomycin. Collectively, these results provide evidence that Bleomycin therapy can accelerate the IVD fibrosis and strengthen the discs’ anti-stress ability without loss of the disc height.

Discussion

The incidence of intervertebral disc degeneration is increasing in an alarming rate in our modern society, and the height loss happened during degeneration is the major cause of neurological symptoms. Following with the height loss was the change of biomechanical characteristic[27] and the possible compression of nerve root in intervertebral foramina[28, 29], so aiming at maintaining even restoring the height is the effective treatment to solve the problem. However, a lack of effective early and mid-term treatment options to maintain the height is available with most end-stage disease treated surgically via discectomy and interbody spinal fusion. Some previous research tried to use the regeneration methods to maintain the disc height, like A bio-scaffold composed of decellularized nucleus pulposus and native nucleus pulposus[30] or just a in situ gelling alginate hydrogel[31] alone, and in our research we offered a new hypothesis that the reparative fibrosis model combined BMSCs and Bleomycin might be an alternative choice to treat IVDD.

Disc fibrosis is in fact a compensatory process during disc degeneration, but the cells functioned during this process still has been debated during the past few years. Some researchers have found that there are some proliferated cells which shared same markers with MSCs in the human degenerated IVDs [32, 33], these cells are distributed mainly in the endplate or outer AF region[34] and their migration rate and endogenous repair mechanism still need to be determined[16, 35]. From our previous observations in patients, we observed fibrotic changes in the acute phase of lumbar disc herniation as well as fibrosis of
the intervertebral disc after percutaneous endoscopic lumbar discectomy. Such changes could represent an initial compensatory protective mechanism to maintain the height of the intervertebral disc and spine, which the MSCs may play an important and initial role during this process. Hence from our perspective, we advocate to activate the MSCs and fibroblast-like cells, promote its ability of migration and collagen deposition aiming at finally alternate the declining NP tissues and successfully maintain even restore the disc height. The induction of reparative and fast fibrosis in degenerative intervertebral discs could offer a way for tissue repair and spine stabilization. We and others have previously shown that reparative fibrosis define here as the formation of organized scar tissue necessary to mechanically stabilize the degenerative intervertebral disc, have potential beneficial effects against the height loss during intervertebral disc degeneration[17, 36]. The use of dermal fibroblast-based cell therapy was found to induce degenerative intervertebral disc fibrosis, prevent the loss of disc height and disc collapse, and maintain the biomechanical properties of the spine[37, 38].

In this study, we use Bleomycin, a chemotherapeutic antibiotic and pro-fibrotic agent, to induce intervertebral disc fibrosis following needle puncture-induced disc degeneration in rats. X-ray radiographs, MRI imaging, and AFM analysis found that the pharmacological induction of fibrosis of the discs by Bleomycin could also maintain intervertebral disc height. BMSCs were complicated during their whole lifespan, our in vitro cell-based assays showed that Bleomycin wouldn't lead to significant change in their cell cycle and apoptosis rate in a short-term use, which preserved the possibility of future clinical usage. Moreover, The short-term Bleomycin could induce BMSCs towards a stronger fibroblast phenotype, although with long-term usage it might cause the cells undergone aging (in some studies the senescence of BMSCs or other cells were found to be associated with the transition into fibrotic phenotype[39, 40]), and for fibroblastic-like cell AF cells it could promote the migration and Collagen deposition via TGFβ-TGFβR1-SMAD2/3 signaling pathway. Bleomycin could upregulate the MMP3 and MMP13 to remodel the ECM (Suppl. Figure 3E), which might help the AF cells to migrate. Despite the structural and compositional differences between healthy NP tissue and fibrotic tissue, the ability of the fibrotic tissue in the NP to maintain the intervertebral disc height may help offset pressure on surrounding tissues and restore some degree of biomechanical stability to the degenerative intervertebral discs.

Mechanistically, we showed using both cellular and molecular-based assays that the TGFβ-TGFβR1-SMAD2/3 is at least involved in the transition of AF cells and BMSCs towards a stronger pro-fibrotic phenotype. This was supported by immunofluorescence staining of intervertebral disc sections from our in vivo intervertebral disc degeneration model which show elevated expression of TGFβ, FSP1 and type I collagen in the AF. TGFβ is a potent pro-fibrotic cytokine central to the development of tissue fibrosis. TGFβ modulates fibroblast proliferation and migration, and stimulates ECM production and collagen deposition[41]. Binding of TGFβ to its target receptor (TGFβRI/ALK5 or TGFβRII) on target cells recruits and activates the receptor-regulated effector proteins (R-SMADs), particularly SMAD2 and SMAD3 through direct C-terminal phosphorylation of an SSXS motif. The activated (phosphorylated) SMAD2/3 form trimeric complexes with SMAD4 to translocate into the nucleus to initiate the activation or repression of target genes in cooperation with other transcription factors[42, 43]. TGFβ-SMAD2/3 signaling pathway has been shown to play a key role in the fibrotic process and the dysregulation of
TGFβ-SMAD2/3 leads to pathological tissue fibrosis of the lung, liver, and kidney[44-47]. Acting through the TGFβ-TGFβR1-SMAD2/3 axis, we found that Bleomycin promoted migration of AF cells and BMSCs, and also upregulated the expression of key ECM genes such as type 1 collagen as well as type 3 collagen, FN1 in AF cells[48-50]. Pharmacological inhibition of TGFβ signaling with LY346947, a TGFβR1 kinase inhibitor, or with TGFβR1 gene silencing, significantly attenuated the Bleomycin-induced cell migration.

**Conclusion**

Our pilot study has demonstrated the potential of Bleomycin-induced fibrosis in the management of intervertebral disc degeneration. Bleomycin-induced fibrosis not only maintains intervertebral disc height but also improves the stress tolerance of the degenerative disc. Certainly, more detailed investigations are needed to warrant the potential usefulness of Bleomycin therapy for the treatment of intervertebral disc degeneration in clinical practice.

**Abbreviations**

**IVDD**: intervertebral disc degeneration;

**IVD**: intervertebral disc;

**NP**: nucleus pulposus;

**AF**: annulus fibrosus;

**MSCs**: marrow stromal cells;

**LDH**: lumbar disc herniation;

**DLS**: degenerative lumbar spondylolisthesis;

**MRI**: magnetic resonance imaging;

**AFM**: atomic force microscopy;

**ECM**: extracellular matrix;

**Declarations**

**Ethics approval and consent to participate**

Human Ethics approval were received from the Institutional Human Ethics Review Board of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (Approval#SH9H-2020-TK265-1). And the Animals Ethics approval were received from the Institutional Animal Ethics Review
Board of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (Approval#SH9H-2020-A559-1).

Consent for publication

Written informed consent for publication was obtained from all participants.

Availability of data and materials

All data and materials included in this study are available upon request by contact with the corresponding author.

Competing interests

The authors have declared that no competing interests exist.

Funding

The work was supported by grants from the National Natural Science Foundation of China (81871790, 81572768 and 81972136) and the Shanghai Hospital Development Center Foundation (SHDC12016110 and 16CR3030A).

Authors' contributions

Jie Zhao, Tangjun Zhou and An Qin guided all the studies. Xiao Yang, Zhiqian Chen performed the experiments, organized the data, and drafted the manuscript. Yifan Zhou and Chen Chen performed the statistical analysis. Chen Han and Xunlin Li helped to draft the manuscript. Haijun Tian, Xiaofei Cheng and Kai Zhang participated in its design. All authors read and approved the final manuscript.

Acknowledgement

We thank Professor Di Chen (Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA) for providing NP and AF cells. The work was supported by grants from the National Natural Science Foundation of China (81871790, 81572768 and 81972136) and the Shanghai Hospital Development Center Foundation (SHDC12016110 and 16CR3030A).

References

1. Frapin L, Clouet J, Delplace V, Fusellier M, Guicheux J, Le Visage C: Lessons learned from intervertebral disc pathophysiology to guide rational design of sequential delivery systems for therapeutic biological factors. Adv Drug Deliv Rev 2019, 149-150:49-71.

2. Smith LJ, Nerurkar NL, Choi K-S, Harfe BD, Elliott DM: Degeneration and regeneration of the intervertebral disc: lessons from development. Dis Model Mech 2011, 4(1):31-41.
3. Walter BA, Torre OM, Laudier D, Naidich TP, Hecht AC, Iatridis JC: Form and function of the intervertebral disc in health and disease: a morphological and stain comparison study. J Anat 2015, 227(6):707-716.

4. Urban JPG, Roberts S: Degeneration of the intervertebral disc. Arthritis Res Ther 2003, 5(3):120-130.

5. Roughley PJ: Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. Spine 2004, 29(23):2691-2699.

6. Sakai D, Grad S: Advancing the cellular and molecular therapy for intervertebral disc disease. Adv Drug Deliv Rev 2015, 84:159-171.

7. Ding F, Shao Z-w, Xiong L-m: Cell death in intervertebral disc degeneration. Apoptosis 2013, 18(7):777-785.

8. Urban JPG, Smith S, Fairbank JCT: Nutrition of the intervertebral disc. Spine 2004, 29(23):2700-2709.

9. Wilkens P, Scheel IB, Grundnes O, Hellum C, Storheim K: Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA 2010, 304(1):45-52.

10. Raj PP: Intervertebral disc: anatomy-physiology-pathophysiology-treatment. Pain Pract 2008, 8(1):18-44.

11. Buchowski JM, Adogwa O: What's New in Spine Surgery. J Bone Joint Surg Am 2019, 101(12):1043-1049.

12. Harrop J, Youssef J, Maltenfort M, Vorwald P, Jabbour P, Bono C, Goldfarb N, Vaccaro A, Hilibrand A: Lumbar Adjacent Segment Degeneration and Disease After Arthrodesis and Total Disc Arthroplasty. Spine 2008, 33:1701-1707.

13. Richardson SM, Hoyland JA, Mobasher R, Csaki C, Shakibaei M, Mobasheri A: Mesenchymal stem cells in regenerative medicine: Opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. Journal of Cellular Physiology 2010, 222(1):23-32.

14. Sakai D: Stem Cell Regeneration of the Intervertebral Disk. Orthopedic Clinics of North America 2011, 42(4):555-562.

15. Orozco L, Soler R, Morera C, Alberca M, Sánchez A, García-Sancho J: Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation 2011, 92(7):822-828.

16. Tzaan WC, Chen HC: Investigating the possibility of intervertebral disc regeneration induced by granulocyte colony stimulating factor-stimulated stem cells in rats. Adv Orthop 2011, 2011.

17. Chen C, Zhou T, Sun X, Han C, Zhang K, Zhao C, Li X, Tian H, Yang X, Zhou Y et al: Autologous fibroblasts induce fibrosis of the nucleus pulposus to maintain the stability of degenerative intervertebral discs. Bone Research 2020, 8(1):7.

18. Sun Y, Gu H, Yang X, Cai R, Shang Y, Hu L, Wang Y, Chen H, Lin X: Bleomycin Polidocanol Foam (BPF) Stability - In Vitro Evidence for the Effectiveness of a Novel Sclerosant for Venous Malformations. Eur J Vasc Endovasc Surg 2020.
19. Jin Y, Zou Y, Hua C, Chen H, Yang X, Ma G, Chang L, Qiu Y, Lyu D, Wang T et al: Treatment of Early-stage Extracranial Arteriovenous Malformations with Intraliesional Interstitial Bleomycin Injection: A Pilot Study. *Radiology* 2018, 287(1):194-204.

20. Yang X, Jin Y, Lin X, Chen H, Ma G, Hu X, Qiu Y, Yu W, Chang L, Wang T: Management of periorbital microcystic lymphatic malformation with blepharoptosis: Surgical treatment combined with intraliesional bleomycin injection. *J Pediatr Surg* 2015, 50(8):1393-1397.

21. Oh C-d, Im H-J, Suh J, Chee A, An H, Chen D: Rho-Associated Kinase Inhibitor Immortalizes Rat Nucleus Pulposus and Annulus Fibrosus Cells: Establishment of Intervertebral Disc Cell Lines With Novel Approaches. *Spine* 2016, 41(5):E255-E261.

22. Sun L, Mao M, Yan Z, Zuo C, Zhang X: A Chinese Traditional Therapy for Bleomycin-Induced Pulmonary Fibrosis in Mice. *Can Respir J* 2018, 2018:8491487.

23. Olive PL, Banáth JP: The comet assay: a method to measure DNA damage in individual cells. *Nat Protoc* 2006, 1(1):23-29.

24. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, Boomershine CS, Ortiz C, Sherrill TP, McMahon FB, Gleaves LA et al: TGFβ signaling in lung epithelium regulates bleomycin-induced alveolar injury and fibroblast recruitment. *Am J Physiol Lung Cell Mol Physiol* 2011, 300(6):L887-L897.

25. Vogt J, Traynor R, Sapkota GP: The specificities of small molecule inhibitors of the TGFβ and BMP pathways. *Cell Signal* 2011, 23(11):1831-1842.

26. Cheng F, Shen Y, Mohanasundaram P, Lindström M, Ivaska J, Ny T, Eriksson JE: Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF-β-Slug signaling. *Proc Natl Acad Sci USA* 2016, 113(30):E4320-E4327.

27. Vergroesen P-PA, Emanuel KS, Peeters M, Kingma I, Smit TH: Are axial intervertebral disc biomechanics determined by osmosis? *J Biomech* 2018, 70:4-9.

28. Qian Y, Qin A, Zheng MH: Transforaminal ligament may play a role in lumbar nerve root compression of foraminal stenosis. *Med Hypotheses* 2011, 77(6):1148-1149.

29. Kitab SA, Miele VJ, Lavelle WF, Benzel EC: Pathoanatomic basis for stretch-induced lumbar nerve root injury with a review of the literature. *Neurosurgery* 2009, 65(1).

30. Zhou X, Wang J, Huang X, Fang W, Tao Y, Zhao T, Liang C, Hua J, Chen Q, Li F: Injectable decellularized nucleus pulposus-based cell delivery system for differentiation of adipose-derived stem cells and nucleus pulposus regeneration. *Acta Biomater* 2018, 81:115-128.

31. Growney Kalaf EA, Pendyala M, Bledsoe JG, Sell SA: Characterization and restoration of degenerated IVD function with an injectable, in situ gelling alginate hydrogel: An in vitro and ex vivo study. *J Mech Behav Biomed Mater* 2017, 72:229-240.

32. Blanco JF, Graciani IF, Sanchez-Guijo FM, Muntión S, Hernandez-Campo P, Santamaria C, Carrancio S, Barbado MV, Cruz G, Gutierrez-Cosío S et al: Isolation and characterization of mesenchymal stromal cells from human degenerated nucleus pulposus: Comparison with bone marrow mesenchymal stromal cells from the same subjects. *Spine* 2010, 35(26):2259-2265.
33. Liu LT, Huang B, Li CQ, Zhuang Y, Wang J, Zhou Y: Characteristics of stem cells derived from the degenerated human intervertebral disc cartilage endplate. PLoS ONE 2011, 6(10):e26285.

34. Henriksson HB, Svala E, Skiolebrand E, Lindahl A, Brisby H: Support of concept that migrating progenitor cells from stem cell niches contribute to normal regeneration of the adult mammal intervertebral disc: A descriptive study in the New Zealand white rabbit. Spine 2012, 37(9):722-732.

35. Henriksson H, Thornemo M, Karlsson C, Hagg O, Junveik K, Lindahl A, Brisby H: Identification of cell proliferation zones, progenitor cells and a potential stem cell niche in the intervertebral disc region: a study in four species. Spine (Phila Pa 1976) 2009, 34(21):2278-2287.

36. Liu J, Wang Y, Song L, Zeng L, Yi W, Liu T, Chen H, Wang M, Ju Z, Cong Y-S: A critical role of DDRGK1 in endoplasmic reticulum homoeostasis via regulation of IRE1α stability. Nature Communications 2017, 8(1):14186.

37. Chee A, Shi P, Cha T, Kao T-H, Yang S-H, Zhu J, Chen D, Zhang Y, An HS: Cell Therapy with Human Dermal Fibroblasts Enhances Intervertebral Disk Repair and Decreases Inflammation in the Rabbit Model. Global Spine J 2016, 6(8):771-779.

38. Shi P, Chee A, Liu W, Chou P-H, Zhu J, An HS: Therapeutic effects of cell therapy with neonatal human dermal fibroblasts and rabbit dermal fibroblasts on disc degeneration and inflammation. Spine J 2019, 19(1):171-181.

39. Nguyen HQ, To NH, Zadigue P, Kerbrat S, De La Taille A, Le Gouvello S, Belkacemi Y: Ionizing radiation-induced cellular senescence promotes tissue fibrosis after radiotherapy. A review. Crit Rev Oncol Hematol 2018, 129:13-26.

40. Cárdenes N, Álvarez D, Sellarés J, Peng Y, Corey C, Wecht S, Nouraie SM, Shanker S, Sembrat J, Bueno M et al: Senescence of bone marrow-derived mesenchymal stem cells from patients with idiopathic pulmonary fibrosis. Stem Cell Res Ther 2018, 9(1):257.

41. Coker RK, Laurent GJ, Shahzeidi S, Lympa PA, du Bois RM, Jeffery PK, McAnulty RJ: Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am J Pathol 1997, 150(3):981-991.

42. Shi Y, Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113(6):685-700.

43. Feng X-H, Derynck R: Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005, 21:659-693.

44. Eser PÖ, Jänne PA: TGFβ pathway inhibition in the treatment of non-small cell lung cancer. Pharmacol Ther 2018, 184:112-130.

45. Loboda A, Sobczak M, Jozkowicz A, Dulak J: TGF-β1/Smads and miR-21 in Renal Fibrosis and Inflammation. Mediators Inflamm 2016, 2016:8319283.

46. Higgins SP, Tang Y, Higgins CE, Mian B, Zhang W, Czekay R-P, Samarakoon R, Conti DJ, Higgins PJ: TGF-β1/p53 signaling in renal fibrogenesis. Cell Signal 2018, 43.

47. Walton KL, Johnson KE, Harrison CA: Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis. Front Pharmacol 2017, 8:461.
48. Schönherr E, Järveläinen HT, Sandell LJ, Wight TN: Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. *J Biol Chem* 1991, **266**(26):17640-17647.

49. Yuan W, Varga J: Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. *J Biol Chem* 2001, **276**(42):38502-38510.

50. Giannandrea M, Parks WC: Diverse functions of matrix metalloproteinases during fibrosis. *Dis Model Mech* 2014, **7**(2):193-203.

### Tables

**Table 1: patient information**

| Name | Pfirrmann Grade | Gender | Age | Diagnosis |
|------|----------------|--------|-----|-----------|
| Z    | 3              | male   | 49  | LDH       |
| G    | 4              | male   | 51  | LDH       |
| S    | 5              | female | 62  | DLS       |
| T    | 3              | male   | 56  | LDH       |
| T*   | 5              | male   | 62  | LDH       |
| Zh   | 4              | female | 53  | LDH       |
| L    | 4              | female | 65  | DLS       |
| W    | 3              | male   | 30  | LDH       |
| L    | 5              | male   | 74  | LDH       |
| Y    | 5              | female | 39  | LDH       |
| M    | 4              | male   | 57  | LDH       |
| Ya   | 3              | female | 36  | LDH       |

**Table 2: PCR primers information**
| Gene   | Accession Number | Description | 5’-Primer-3’ |
|--------|-----------------|-------------|--------------|
| Fn1    | NM_019143.2     |             | GGATCCCCTCCCAGAGAAGT |
|        |                 |             | GGTTGTTGAAAGCTACAG |
| Col1a1 | NM_053304.1     |             | GGATCGACCCTAAACCAAGG |
|        |                 |             | GATCGGAACCTTCGGCTCAG |
| Col3a1 | NM_032085.1     |             | AGTTGGCTATAGGGAAGG |
|        |                 |             | CACCTTTGTCACCTCGTGA |
| TGFβR1 | NM_012775.2     |             | TGCTGCCTTCCTCTGAGT |
|        |                 |             | TGCCTTCCTGTGATGAGT |
| TGFβR2 | NM_031132.3     |             | CCAAGTCGGTTAACAGG |
|        |                 |             | TGAAACGGTGGTAGGAG |
| TGFβR3 | NM_017256.1     |             | GAGGGGCTGTCATTTACAC |
|        |                 |             | CTAATCCCCCTCCTGACCA |
| TGFβ1  | NM_021578.2     |             | CACTCCCCTGCGCTTACG |
|        |                 |             | GGACTGGGAGCCCTTTAG |
| MMP3   | NM_133523.3     |             | TTTGGCCTCTTCTTCATCC |
|        |                 |             | GCATCGATCTTCTGGAGG |
| MMP13  | NM_133530.1     |             | TGCTGCATAAGGAGACG |
|        |                 |             | TGTCCTTAAAGCTAACAG |
| Timp1  | NM_012886.2     |             | AAATACCTTCTTCTGGG |
|        |                 |             | TAGAAAGTCTTCCGGT |
| P21    | NM_017198.1     |             | TCCCTCTGGGCTATTACG |
|        |                 |             | GGTGTTTCTCATGGAGG |
| CDK1   | NM_019296.1     |             | GGAACAGAGAGGGTCGTG |
|        |                 |             | GCACCTTCTTCTCCTGG |
| CDK2   | NM_199501.1     |             | TGCTATCAGCCAGAGGG |
|        |                 |             | GGCTGTTACATCTGGAAAG |
| CDK4   | NM_053593.2     |             | GACGATCCGCCGTGGT |
|        |                 |             | TCAGGTCCCGGTAACAG |
| CDK6   | NM_001191861.1  |             | TGCTGGAAAGTCTCAGG |
|        |                 |             | CGACCTTGGAGGAAG |
| CCNG2  | NM_001105725.2  |             | ACCCTGTGGAAGCGGAA |
|        |                 |             | TGCCACCATGTAACACA |
| CCND2  | NM_022267.1     |             | GATGATCGCAACTGGAGG |
|        |                 |             | TGCTCCGGATCTTACAGA |